Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus oxaliplatin perioperative therapy in elderly gastric/gastroesophageal junction adenocarcinoma
ChiCTR2400091149Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trifluridine + tipiracil and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Pathologic complete response rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
trifluridine + tipiraciloxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400091149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091149.